Chemical structures symptoms and conditions

I've been taking Celexa for about 10 years now...in beginning it was 40mg and it took a good 3 weeks to totally be free of the horrible depression/panic/anxiety attacks that came on me like a flood. I was in bad shape when I finally found out what was wrong with me and I was a total basket case for a month before and 3 weeks after. When the drug took effect slowly I came out of this horrible funk. The side effects mostly were sleepiness, loss of sex drive and sensation like many here are experiencing. Gradually I tapered down to 20mg and now 10mg. I don't take it everyday but about every other day and just enough to keep some in my system so that if I nose dive again I up my dose and it doesn't take as long to feel normal. I don't handle trauma, stress or confrontations well and they have a tendency to make me switch into these nose dives. Celexa and dosage works for ME...I believe each one of us has different chemical structures which is why one pill doesn't work for all of us. I think high dosages tend to make you more "zombie" too. I've tried other types of anti depressants and always come back to Celexa because the side effects aren't anything like the others to me. So, please keep trying different meds to see whats good for YOU. If a doctor gives you a hard time, FIND ANOTHER! I suggest a Psychiatric one too. GP's and OB/GYN's aren't trained enough in this area to really know how to prescribe and help treat this and have a tendency to prescribe what they've been given freebies of. Not all Psych's are good either. Keep trying to find the right one please! I know, I've been there. Above all, pray....it helps. :)

The example that I am posting below is not the only patent for an aminoquinoline derivative that is proposed for the treatment of neuro-psychiatric disorders. Even though we are not comparing exact chemical structures, it is certainly worth considering how the quinolines relate to this receptor.

It is also worth considering why montelukast, a quinoline, seems to be causing some of the problems that this owners of this particular patent think that they can treat.

As I mentioned before, I have no answers. Regardless of how small Merck believes the population of Singulair patients who suffer neuro-psychiatric disorders is, I do not believe that any patient should be ignored. It also seems that many companies have studied this area in depth and more than one company knows a lot more than we know about why it is possible for these side effects to happen.

" The compounds of formula I have a good activity on the 5-HT.sub.5A receptor. Therefore, the invention further provides methods for the treatment of depression (which term includes bipolar depression, unipolar depression, single or recurrent major depressive episodes with or without psychotic features, catatonic features, melancholic features, atypical features or postpartum onset, seasonal affective disorders and dysthymia, depressive disorders resulting from a general medical condition including, but not limited to, myocardial infarction, diabetes, miscarriage or abortion), anxiety disorders, (which includes generalized anxiety and social anxiety disorder, panic disorders, agoraphobia, social phobia, obsessive compulsive disorders, post-traumatic stress disorders, psychotic disorders (which includes schizophrenia, schizoaffective disorders, bipolar disease, mania, psychotic depression, and other psychoses involving paranoia and delusions), pain (particularly neuropathic pain), memory disorders (including dementia, amnesic disorders and age-associated memory impairment), disorders of eating behaviors (including nervosa and bulimia nervosa), sexual dysfunction, sleep disorders (including disturbances of circadian rhythm, dyssomnia, insomnia, sleep apnea and narcolepsy), withdrawal from abuse of drugs (such as of cocaine, ethanol, nicotine, benzodiazepines, alcohol, caffeine, phencyclidine and phencyclidine-like compounds, opiates such as cannabis, heroin, morphine, sedative hypnotic, amphetamine or amphetamine-related drugs), motor disorders such as Parkinson's disease, dementia in Parkinson's disease, neuroleptic-induced Parkinsonism and tardive dyskinesias, as well as other psychiatric disorders and gastrointestinal disorders such as irritable bowel syndrome (WO 2004/096771). "

******